I'll have to have a read, thanks for sharing.

First 60 Last

Share
Profile

Follow
pastperformer

7,426 Posts.

2239

25/06/24

11:39

Post #: 74475948
Share

Originally posted by TonyIndo: ↑

Resmed are tracking a cohort of over 0.5 million patients with prescriptions for both GLP-1 medications and positive airway pressure therapy. This data can be reviewed on their website. What have they found? That some of the market thought that patients on GLP-1 medications would be less likely to start positive airway pressure therapy. Resmed stated that this was and still is not the case (listen to their last Earnings Call on their website to understand why). But in summary, their analysis of over 529,000 patients with GLP-1 prescriptions shows that not only is there not a reduction in the propensity to start positive airway pressure therapy, it is the exact opposite.

For patients who have been prescribed a GLP-1, there is an increase of 10% of the absolute percentage of patients that commence positive airway pressure therapy. That's a potential increase of 10% into the funnel folks!! For example if 75% patient new starts in a given period increase by that 10% to 85% that's a bigger market every year. Their thoughts are that these GLP-1 medications will lead to greater growth of patients coming into their health care system over time. Just look at how many patients they have that they can track in their cohort. Resmed's data (529,000 plus patients) is showing that with that cohort of patients. Their goal is to leverage the demand that's coming from this new megatrend of GLP-1's.

Another important thing to note is that these GLP-1s are the latest generation medications.

Trial phase iii was only a small trial less than 500 patients.

Tony

Expand

I'll have to have a read, thanks for sharing.

RMD Price at posting: $27.93 Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

CTT

Cettire shares jump on FY24 revenue growth up 80% vs pcp – but stock still badly bruised

NWC

New World Resources inks complete PFS for Antler Copper Project in Arizona, USA

ATH

Trial for Alterity's neurodegenerative drug ATH434 shows reduced disability

LRL

Labyrinth shares rocket by 219% on news of Comet Vale and Vivien gold project acquisitions

VMM

Virdis Mining flags breakthrough with 76% neodymium and praseodymium recoveries

There are more pages in this discussion • 5 more messages in this thread...

First 60 Last

Add RMD (ASX) to my watchlist

(20min delay)
Last $30.70		Change 0.215(0.71%)		Mkt cap ! $19.41B

Open	High	Low	Value	Volume
$30.52	$30.72	$30.49	$13.04M	425.9K

Buyers (Bids)

No.	Vol.	Price($)
10	767	$30.69

Sellers (Offers)

Price($)	Vol.	No.
$30.70	270	4

View Market Depth

No.	Vol.	Price($)
8	596	30.690
11	1350	30.680
6	1004	30.670
7	1708	30.660
3	769	30.650

Price($)	Vol.	No.
30.700	256	6
30.710	1690	6
30.720	955	9
30.730	1283	4
30.740	1311	4

Last trade - 13.41pm 17/07/2024 (20 minute delay)

RMD (ASX) Chart

I'll have to have a read, thanks for sharing.

Cettire shares jump on FY24 revenue growth up 80% vs pcp – but stock still badly bruised

New World Resources inks complete PFS for Antler Copper Project in Arizona, USA

Trial for Alterity's neurodegenerative drug ATH434 shows reduced disability

Labyrinth shares rocket by 219% on news of Comet Vale and Vivien gold project acquisitions

Virdis Mining flags breakthrough with 76% neodymium and praseodymium recoveries

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

I'll have to have a read, thanks for sharing.

Top Stories

Cettire shares jump on FY24 revenue growth up 80% vs pcp – but stock still badly bruised

New World Resources inks complete PFS for Antler Copper Project in Arizona, USA

Trial for Alterity's neurodegenerative drug ATH434 shows reduced disability

Labyrinth shares rocket by 219% on news of Comet Vale and Vivien gold project acquisitions

Virdis Mining flags breakthrough with 76% neodymium and praseodymium recoveries

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News